3篇
您的检索式：作者名="Wenzhao Zhong"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology显示文摘Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation. | Xuchao Zhang Zhiyong Liang Shengyue Wang Shun Lu Yong Song Ying Cheng Jianming Ying Weiping Liu Yingyong Hou Yangqiu Li Yi Liu Jun Hou Xiufeng Liu Jianyong Shao Yanhong Tai Zheng Wang Li Fu Hui Li Xiaojun Zhou Hua Bai Mengzhao Wang You Lu Jinji Yang Wenzhao Zhong Qing Zhou Xuening Yang Jie Wang Cheng Huang Xiaoqing Liu Xiaoyan Zhou Shirong Zhang Hongxia Tian Yu Chen Ruibao Ren Ning Liao Chunyan Wu Zhongzheng Zhu Hongming Pan Yanhong Gu Liwei Wang Yunpeng Liu Suzhan Zhang Tianshu Liu Gong Chen Zhimin Shao Binghe Xu Qingyuan Zhang Ruihua Xu Lin Shen Yilong Wu | 2019 | Cancer Biology & Medicine2019，16，1： | 14 |
| 2 | An intrinsically self-healing and anti-freezing molecular chains induced polyacrylamide-based hydrogel electrolytes for zinc manganese dioxide batteries显示文摘The anti-freezing strategy of hydrogels and their self-healing structure are often contradictory,it is vital to break through the molecular structure to design and construct hydrogels with intrinsic anti-freezing/self-healing for meeting the rapid development of flexible and wearable devices in diverse service conditions.Herein,we design a new hydrogel electrolyte(AF/SH-Hydrogel)with intrinsic anti-freezing/self-healing capabilities by introducing ethylene glycol molecules,dynamic chemical bonding(disulfide bond),and supramolecular interaction(multi-hydrogen bond)into the polyacrylamide molecular chain.Thanks to the exceptional freeze resistance(84%capacity retention at-20℃)and intrinsic self-healing capabilities(95%capacity retention after 5 cutting/self-healing cycles),the obtained AF/SH-Hydrogel makes the zinc||manganese dioxide cell an economically feasible battery for the state-of-the-art applications.The Zn||AF/SH-Hydrogel||MnO_(2)device offers a near-theoretical specific capacity of 285 m A h g^(-1)at 0.1 A g^(-1)(Coulombic efficiency≈100%),as well as good self-healing capability and mechanical flexibility in an ice bath.This work provides insight that can be utilized to develop multifunctional hydrogel electrolytes for application in next generation of self-healable and freeze-resistance smart aqueous energy storage devices. | Haiyang Liao Wenzhao Zhong Chen Li Jieling Han Xiao Sun Xinhui Xia Ting Li Abolhassan Noori Mir F.Mousavi Xin Liu Yongqi Zhang | 2024 | Journal of Energy Chemistry2024，89，2： | 0 |
| 3 | The earlier,the better?A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer显示文摘Immune checkpoint inhibitors(ICIs)have revolutionized the approach to advanced and locally advanced non-small-cell lung cancer(NSCLC).Antibodies blocking inhibitory immune checkpoints,such as programmed death 1(PD-1)and its ligand(PD-L1),have remarkable antitumor efficacy and have been approved as a standard first-or second-line treatment in non-oncogene-addicted advanced NSCLC.The successful application of immunotherapy in advanced lung cancer has motivated researchers to further evaluate its clinical role as a neoadjuvant setting for resectable NSCLC and for improved long-term overall survival and curative rates.In this review,we discuss the efforts that incorporate ICIs into the treatment paradigm for surgically resectable lung cancer.We reviewed the early-phase results from neoadjuvant clinical trials,the landscape of the majority of ongoing phase III trials,and discuss the prospects of ICIs as a curative therapy for resectable lung cancer.We also summarized the potential biomarkers and beneficiaries involved in the current study,as well as the remaining unresolved challenges for neoadjuvant immunotherapy. | Fajiu Li Ying Chen Juanjuan Wu Chenghong Li Shi Chen Ziyang Zhu Wei Qin Min Liu Bingzhu Hu Shuang Liu Wenzhao Zhong | 2022 | Chronic Diseases and Translational Medicine2022，8，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员